Widely read:
Aditya Roy/AI-Generated Image
Summary: Rubicon Research, a pharmaceutical company, is set to go public on October 9, 2025. Though it is among the fastest-growing players in the space, the company faces risks such as tariffs and geopolitical disruptions. Let’s look at whether this IPO is worth subscribing to.
The Rubicon Research IPO (initial public offering) will open for subscription on October 9, 2025 and close on October 13, 2025. The total issue size, worth Rs 1,378 crore, comprises a fresh issue of Rs 500 crore while the remaining Rs 878 crore will be raised via an offer for sale (OFS).
Below is a summary of the pharmaceutical company’s business, financials, strengths, risks and valuation to help you make an informed investing decision.
What the company does
Rubicon Research is a pharmaceutical formulations company focused entirely on regulated markets, especially the US. It develops specialty and drug-device combination products through strong R&D.
The company has been actively expanding its US portfolio, securing multiple ANDA (Abbreviated New Drug Application) and NDA (New Drug Application) approvals from the US FDA, including 12 ANDAs in FY25 alone. Of its 66 commercialised products in the US, nine command over 25 per cent market share by value.
Track record and valuation
Financially, Rubicon Research has shown steady momentum. Between FY23 and FY25, its revenue grew at an impressive 82 per cent annually, while both EBIT and net profit turned positive after losses in FY23. However, the company’s total debt also rose during the same period by more than 14 per cent.
At the upper end of the price band (Rs 485), the stock is expected to be valued at almost 53 times its TTM (trailing twelve months) earnings and 7.3 times its book value. By contrast, Rubicon Research’s peers trade at a P/E of nearly 22 times and a P/B of 4 times.
Rubicon Research IPO details
|
Total IPO size (Rs cr)
|
1,378 |
| Offer for sale (Rs cr) | 878 |
| Fresh issue (Rs cr) | 500 |
| Price band (Rs) | 461-485 |
| Subscription dates | October 9-13, 2025 |
| Purpose of issue | Repayment of debt, funding inorganic growth and other strategic initiatives |
Post-IPO
|
M-cap (Rs cr)
|
7,990 |
| Net worth (Rs cr) | 1,094 |
| Promoter holding (%) | 62.1 |
| Price/earnings ratio (P/E) | 52.5 |
| Price/book ratio (P/B) | 7.3 |
Financial history
| Key financials | 2Y CAGR (%) | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue (Rs cr) | 80.7 | 1,284 | 854 | 394 |
| EBIT (Rs cr) | - | 219 | 116 | -18 |
| PAT (Rs cr) | - | 134 | 91 | -17 |
| Net worth (Rs cr) | 37.4 | 541 | 385 | 286 |
| Total debt (Rs cr) | 14.3 | 418 | 425 | 320 |
| EBIT is earnings before interest and tax PAT is profit after tax |
||||
Ratios
| Key ratios | 3Y average (%) | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| ROE (%) | 16.7 | 29.0 | 27.1 | -5.9 |
| ROCE (%) | 12.7 | 24.8 | 16.3 | -2.9 |
| EBIT margin (%) | 8.7 | 17.1 | 13.5 | -4.5 |
| Debt-to-equity | 1 | 0.8 | 1.1 | 1.1 |
| ROE is return on equity ROCE is return on capital employed |
||||
The good
Below are some of the strengths of Rubicon Research.
#1 Fastest-growing player in the pharma formulations space
Between FY23 and FY25, Rubicon Research was the fastest-growing Indian formulations company, clocking an 81 per cent CAGR, more than seven times the industry average, albeit on a low base. The company has built a strong US portfolio with 66 commercialised products, nine of which hold a market share of over 25 per cent by value.
#2 A data-driven strategy helps sustain margins
The company follows a data-driven, ROI-centric product selection framework that identifies opportunities aligned with its strengths in development, manufacturing and commercialisation. By targeting complex and low-competition generics, it has managed to grow prices by 8 per cent per unit between FY22–25, even as the broader US generics market saw a 5.2 per cent erosion.
Rubicon Research’s specialty portfolio, comprising 16 products including two Validus-branded CNS drugs without generic competition, and one co-developed NDA, contributes significantly to margins. A commercialisation rate of 86.4 per cent and gross margins around 70 per cent reflect the efficiency of its selection framework.
The bad
Here are some of the downsides of Rubicon Research.
#1 Nearly all of the company’s revenue comes from a single market
Over 98 per cent of Rubicon Research’s revenue comes from the United States, making it highly dependent on that market. Thus, any adverse developments such as tariffs, regulatory changes or political and economic disruptions in the US could materially affect its performance.
#2 Client concentration
A major portion of the company’s revenue (over 70 per cent) comes from its top five customers, reflecting a high concentration risk. The loss of even one key client could significantly impact its revenue and growth prospects. This dependence highlights the company’s limited customer diversification and potential vulnerability to client-specific disruptions.
#3 High working capital requirements
Rubicon Research’s business is working-capital intensive, demanding steady investment in both operations and capacity. This is evident from its net working capital days, which stood at 172 in FY25, driven by elevated trade receivable and inventory days of 92 and 148, respectively, during the same period.
Therefore, any difficulty in maintaining adequate financing or optimising working capital could strain operations and growth plans.
Where will the IPO proceeds go?
Of the fresh issue size of Rs 500 crore, Rubicon Research plans to utilise Rs 310 crore towards the repayment of debt, while the remaining funds will be directed towards funding its inorganic growth, strategic initiatives and general corporate purposes.
So, should you apply for the Rubicon Research IPO?
The Rubicon Research IPO may catch attention today, but true wealth isn’t built on listing-day excitement. It’s built on patience, quality and conviction.
With Value Research Stock Advisor, you can look beyond the IPO buzz, focus on sound businesses with enduring growth potential and invest where compounding, not hype, does the heavy lifting.
Also read: LG Electronics India IPO: Should you apply?
Disclaimer: This content is for information only and should not be considered investment advice or a recommendation.
For grievances: [email protected]
Ask Value Research 
New episodes every Friday 
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
